FINANCIAL INFORMATION

into in respect of financial products with financial institutions; and the foreign exchange loss
under our foreign exchange forward contracts as a result of the decreasing trend of the U.S.
dollar exchange rate against the Renminbi in 2017.

Research and development expenses

Our research and development expenses increased by 125.7% from approximately
RMB122.0 million for the year ended December 31, 2016 to approximately RMB275.3 million
for the year ended December 31, 2017, mainly due to increases in our clinical trial expenses,
preclinical study costs, staff salary and welfare for research and development personnel and
expenses for depreciation and amortization.

Administrative expenses

Our administrative expenses increased by 72.4% from approximately RMB42.8 million
for the year ended December 31, 2016 to approximately RMB73.8 million for the year ended
December 31, 2017, primarily due to increases in staff salary and welfare for administrative
personnel, depreciation and amortization, office administration expenses and audit and
consultancy fees.

Finance costs

We did not incur any finance cost for the years ended December 31, 2016 and 2017.

Loss before tax

For

the reasons described above, our

loss before tax increased by 144.4% from
approximately RMB131.2 million for the year ended December 31, 2016 to approximately
RMB320.7 million for the year ended December 31, 2017.

Income tax expense

Our income tax expense amounted to RMB0.2 million in 2016. Our income tax expense
amounted to RMB58,000 in 2017, mainly because of the decrease in the deferred tax liabilities
in 2017.

Loss for the year from continuing operations

As a result of the foregoing, loss for the year from continuing operations increased by
144.0% from approximately RMB131.5 million for the year ended December 31, 2016 to
approximately RMB320.8 million for the year ended December 31, 2017.

– 309 –

